Impairments of probabilistic response reversal and passive avoidance following catecholamine depletion.
Catecholamines, particularly dopamine, have been implicated in various aspects of the reward function including the ability to learn through reinforcement and to modify flexibly responses to changing reinforcement contingencies. We examined the impact of catecholamine depletion (CD) achieved by oral administration of alpha-methyl-paratyrosine (AMPT) on probabilistic reversal learning and passive avoidance (PA) in 15 female subjects with major depressive disorder in full remission (RMDD) and 12 healthy female controls. The CD did not affect significantly the acquisition phase of the reversal learning task. However, CD selectively impaired reversal of the 80-20 contingency pair. In the PA learning task, CD was associated with reduced responding toward rewarding stimuli, although the RMDD and control subjects did not differ regarding these CD-induced changes in reward processing. Interestingly, the performance decrement produced by AMPT on both of these tasks was associated with the level of decreased metabolism in the perigenual anterior cingulate cortex. In an additional examination using the affective Stroop task we found evidence for impaired executive attention as a trait abnormality in MDD. In conclusion, this study showed specific effects of CD on the processing of reward-related stimuli in humans and confirms earlier investigations that show impairments of executive attention as a neuropsychological trait in affective illness.
Hasler
Gregor
G
Department of Psychiatry, University Hospital, Zurich, Switzerland. g.hasler@bluewin.ch
Mondillo
Krystal
K
Drevets
Wayne C
WC
Blair
James R
JR
D000293:Adolescent; D000328:Adult; D001362:Avoidance Learning / Q000187:drug effects*; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism*; D002395:Catecholamines / Q000378:metabolism*; D003216:Conditioning, Operant / Q000187:drug effects*; D003865:Major Depressive Disorder / Q000000981:diagnostic imaging / Q000378:metabolism / Q000523:psychology*; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism; D006179:Gyrus Cinguli / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008875:Middle Aged; D049268:Positron-Emission Tomography; D012193:Reversal Learning / Q000187:drug effects*; D012201:Reward; D057190:Stroop Test; D019805:alpha-Methyltyrosine / Q000494:pharmacology
D002395:Catecholamines; D019788:Fluorodeoxyglucose F18; D019805:alpha-Methyltyrosine
Neuroimage. 2007 Feb 15;34(4):1754-65
17188518
J Neurochem. 2004 Feb;88(4):1003-9
14756822
J Neurophysiol. 2006 Mar;95(3):1509-17
16338994
Psychiatry Res. 2001 May 10;102(1):9-20
11368835
Psychol Med. 1999 Nov;29(6):1307-21
10616937
J Neurophysiol. 1996 May;75(5):1970-81
8734596
Neuropsychopharmacology. 2005 Jun;30(6):1138-47
15689962
Nat Neurosci. 2007 Aug;10(8):949-51
17603478
J Biol Chem. 1964 Sep;239:2910-7
14216443
Behav Neural Biol. 1985 Nov;44(3):354-63
3936470
Arch Gen Psychiatry. 2008 May;65(5):521-31
18458204
J Neurophysiol. 2000 Apr;83(4):1864-76
10758098
Neuroimage. 2007 Mar;35(1):430-40
17239620
Eur J Neurosci. 1998 Mar;10(3):1019-26
9753169
Curr Opin Neurobiol. 2004 Dec;14(6):769-76
15582382
J Nerv Ment Dis. 2003 Mar;191(3):175-81
12637844
J Neurosci. 2006 Aug 9;26(32):8360-7
16899731
Pharmacol Biochem Behav. 1981 Mar;14(3):345-51
6785766
Curr Opin Neurobiol. 1997 Apr;7(2):191-7
9142754
Psychol Med. 2002 Jan;32(1):167-72
11885569
Annu Rev Neurosci. 2007;30:259-88
17600522
Cereb Cortex. 2001 Dec;11(12):1136-43
11709484
Arch Gen Psychiatry. 2007 Mar;64(3):327-37
17339521
Neuropsychopharmacology. 2007 Oct;32(10):2125-34
17299511
J Exp Psychol Hum Learn. 1980 Mar;6(2):174-215
7373248
Neuroimage. 2006 Feb 15;29(4):1161-72
16387514
J Exp Psychol Learn Mem Cogn. 2002 Mar;28(2):259-74
11911383
Science. 2004 May 7;304(5672):878-80
15131308
Arch Gen Psychiatry. 2003 Jun;60(6):601-9
12796223
J Abnorm Psychol. 1996 Feb;105(1):34-41
8666709
J Neurosci. 2004 Aug 25;24(34):7540-8
15329401
Nature. 1976 Jan 1-8;259(5538):42-4
175278
J Abnorm Psychol. 1985 Aug;94(3):308-19
4031228
Neuropsychopharmacology. 2007 Jan;32(1):206-15
16900105
Behav Brain Res. 2006 Aug 10;171(2):181-8
16713639
Biol Psychiatry. 2006 Jul 15;60(2):93-105
16406007
Neuropsychopharmacology. 2007 Jan;32(1):180-9
16841074
Ann N Y Acad Sci. 2003 Apr;985:233-50
12724162
Brain. 2008 Mar;131(Pt 3):829-41
18263624
Exp Brain Res. 1970 Nov 26;11(4):376-86
4993199
Neurobiol Learn Mem. 2004 Mar;81(2):155-8
14990236
Cereb Cortex. 2007 Jan;17(1):18-27
16481566
Arch Gen Psychiatry. 1999 May;56(5):395-403
10232292
Mol Psychiatry. 1998 May;3(3):220-6, 190-1
9672897
Mol Psychiatry. 2004 Jun;9(6):557-69
15098002
J Child Psychol Psychiatry. 2005 Sep;46(9):972-81
16109000
Prog Neurobiol. 1998 Jul;55(4):343-61
9654384
J Abnorm Psychol. 1986 Aug;95(3):252-6
3745647
Neuropsychopharmacology. 2004 Oct;29(10):1765-81
15213704